Key clinical point: A test using methylation patterns in plasma cell-free DNA performs well at detecting cancer of different types and stages.
Major finding: Specificity was 99.3%. Sensitivity for stage I-III of a dozen cancers causing nearly two-thirds of U.S. cancer deaths was 67.3%.
Study details: A prospective case-control substudy to develop and validate a classifier using plasma cell-free DNA methylation patterns among 6,689 participants (2,482 with diverse cancers and 4,207 without cancer).
Disclosures: Dr. Liu disclosed that the Mayo Clinic was compensated for her advisory board activities for GRAIL Inc. The study was supported by GRAIL and by Princess Margaret Cancer Centre’s McCain Genitourinary BioBank in the department of surgical oncology.
Liu MC et al. Ann Oncol. 2020 Mar 31. doi: 10.1016/j.annonc.2020.02.011